Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aratana Therapeutics Inc (NASDAQ:PETX)

6.45
Delayed Data
As of Oct 18
 +0.03 / +0.47%
Today’s Change
4.97
Today|||52-Week Range
9.23
-10.17%
Year-to-Date
Exelixis Pops as FDA Gives Kidney Cancer Drug Priority Review -- Biotech Movers
Oct 16 / TheStreet.com - Paid Partner Content
3 Biotech Values in a Fully Valued Market
Oct 15 / TheStreet.com - Paid Partner Content
Exelisis Pops as FDA Gives Kidney Cancer Drug Priority Review -- Biotech Movers
Oct 16 / TheStreet.com - Paid Partner Content
3 Biotech Values in a Fully Valued Market
Oct 13 / TheStreet.com - Paid Partner Content
Exelisis Soars After FDA Grants Priority Review for Kidney Cancer Drug
Oct 16 / TheStreet.com - Paid Partner Content